ALDX Aldeyra Therapeutics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Aldeyra Therapeutics, Inc. (ALDX) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 27, 2026, a 10-Q quarterly report filed on November 5, 2025, an 8-K current report filed on May 1, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Aldeyra Therapeutics, Inc. (ALDX) (SEC CIK 1341235), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Aldeyra Therapeutics, Inc. (ALDX) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | May 1, 2026 | — | — | — |
8-K | Apr 20, 2026 | — | — | — |
8-K | Apr 1, 2026 | — | — | — |
8-K | Mar 17, 2026 | — | Analysis | — |
10-K | Feb 27, 2026 | Dec 31, 2025 | — | |
8-K | Dec 31, 2025 | — | — | |
8-K | Dec 16, 2025 | — | — | |
10-Q | Nov 5, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 14, 2025 | Mar 31, 2025 | — | |
10-K | Feb 28, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 1, 2024 | Jun 30, 2024 | — | |
10-Q | May 2, 2024 | Mar 31, 2024 | — | |
10-K | Mar 7, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 3, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 3, 2023 | Jun 30, 2023 | — | |
10-Q | May 4, 2023 | Mar 31, 2023 | — | |
10-K | Mar 9, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 10, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 5, 2022 | Jun 30, 2022 | — | |
10-Q | May 5, 2022 | Mar 31, 2022 | — | |
10-K | Mar 17, 2022 | Dec 31, 2021 | — | |
10-Q | Oct 28, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 5, 2021 | Jun 30, 2021 | — |
Frequently Asked Questions
What are the latest ALDX SEC filings in 2026?
Aldeyra Therapeutics, Inc. (ALDX) has filed a 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on May 1, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did ALDX file its most recent 10-K annual report?
Aldeyra Therapeutics, Inc. (ALDX) filed its most recent 10-K annual report on February 27, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view ALDX 10-Q quarterly reports?
Aldeyra Therapeutics, Inc. (ALDX)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every ALDX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has ALDX filed recently?
Aldeyra Therapeutics, Inc. (ALDX)'s most recent 8-K was filed on May 1, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find ALDX insider trading activity (Form 4)?
SignalX aggregates every ALDX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does ALDX file with the SEC?
Aldeyra Therapeutics, Inc. (ALDX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ALDX filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Aldeyra Therapeutics, Inc. (ALDX).
What is ALDX's SEC CIK number?
Aldeyra Therapeutics, Inc. (ALDX)'s SEC CIK (Central Index Key) number is 1341235. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1341235 to look up all ALDX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find ALDX return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Aldeyra Therapeutics, Inc. (ALDX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Aldeyra Therapeutics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 54+ filings.